Review
Jul 2026
The PDPK1–RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas
Targeting a shared signaling pathway might help overcome resistance seen with traditional precision medicine and support the development of new therapies for rare disease subtypes, despite their genetic and phenotypic differences.
Junya Kuroda, T. Tsukamoto, Y. Shimura
· Expert opinion on therapeuti... · 0 citations